Gemini Therapeutics announced the appointment of Claude Knopf as chief business officer and Sandra Rojas-Caro, M.D., as chief medical officer. In parallel, the company also announced the promotion of senior vice president for process development and manufacturing, Scott Lauder, Ph.D., to chief technology officer. A seasoned executive and biotech veteran, Mr. Knopf joins Gemini from Pieris Pharmaceuticals, where he served as senior vice president and chief business officer and helped close key transformative partnering deals. Prior to that, he was senior vice president BD&L/M&A for Baxter Bioscience, and the spin-off Baxalta, where he helped expand the Oncology business and pipeline and strengthened the company’s Hematology and Immunology divisions. As chief business officer, Mr. Knopf will lead corporate development and oversee key operational functions as Gemini continues its growth trajectory and transitions to the next stage of its focused business model. Dr. Rojas-Caro brings more than 20 years of experience across all phases of drug development, including successful global submissions, applied technology and translational biology environments. She was previously chief medical officer for Aeglea BioTherapeutics. Prior to Aeglea, she served as group vice president of clinical research and development at Synageva BioPharma. As chief medical officer, Dr. Rojas-Caro will oversee the development and implementation of clinical and regulatory strategy and operations as Gemini advances multiple product development programs into the clinic. Dr. Lauder is a protein chemist with a deep background in biologics CMC development—from discovery through manufacturing. Prior to joining Gemini, Dr. Lauder served as vice president of process sciences and clinical manufacturing at Merrimack Pharmaceuticals and global head of the Protein and Cell Sciences group at EMD Serono. In his new role as chief technology officer, Dr. Lauder will oversee Gemini’s CMC team and development of translational technology for the company’s precision therapeutics.